Constantin G. Ioannides

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Bryan Fisk, Tana Blevins, J. Taylor Wharton et al. · The Journal of Experimental Medicine · 1995 · 542 citations · Full text

Life Sciences, Immunology, Oncology +17

BRAK/CXCL14 Is a Potent Inhibitor of Angiogenesis and a Chemotactic Factor for Immature Dendritic Cells

Thomas D. Shellenberger, Mary Wang, Manu Gujrati et al. · Cancer Research · 2004 · 247 citations

Medicine, Cancer Biology, Oncology +17

Clinical Trial Results of a HER2/<i>neu</i> (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients

George E. Peoples, Jennifer M. Gurney, Mike M. Woll et al. · Journal of Clinical Oncology · 2005 · 214 citations

Medicine, Immunology, Oncology +17

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

Constantin G. Ioannides, Bryan Fisk, Keith R. Jerome et al. · The Journal of Immunology · 1993 · 211 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

Jennifer M. Gurney, Matthew T. Hueman, Michael Woll et al. · Journal of Clinical Oncology · 2005 · 183 citations

Medicine, Immunology, Oncology +17